Has Colin Vale, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,093 in general payments to Colin Vale, MD across 15 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Colin Vale, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Colin Vale, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Colin Vale, MD

Internal Medicine · Atlanta, GANPI 1982082467

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Syndax Pharmaceuticals, Inc. accounts for 89.1% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $4,758, more than ten times the $23 reported in 2021. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,093in general payments, 2019–2025

Across 15 payments — averaging $339.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Syndax Pharmaceuticals, Inc.$5K
Sanofi-aventis U.S. LLC$144
Sanofi$100
Adaptive Biotechnologies Corporation$98
Sobi, Inc$84
Astellas Pharma US Inc$69
plus $62 from 3 others

$87,570in research payments, 2019–2025

Across 19 payments — averaging $4608.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Incyte Corporation$68K
National Marrow Donor Program$20K

What the payments were for

Consulting fees$2,78055%
Travel & lodging$1,54430%
Food & beverage$70014%
Education$691%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Syndax Pharmaceuticals, Inc.	7	$4,535
Sanofi-aventis U.S. LLC	1	$144
Sanofi	1	$100
Adaptive Biotechnologies Corporation	1	$98
Sobi, Inc	1	$84
Astellas Pharma US Inc	1	$69
Autolus Inc	1	$25
Jazz Pharmaceuticals Inc.	1	$23
Gilead	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,093 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia →

Medicare billing

Part B allowed, 2024

$42,633

Medicare patients

Services billed

570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
TibsovoIvosidenib	15	$384,341
OnuregAzacitidine	17	$377,992
VenclextaVenetoclax	35	$225,026
PrevymisLetermovir	24	$175,200
ValacyclovirValacyclovir Hcl	67	$1,819
Oxycodone Hcl	47	$285
Prochlorperazine Maleate	32	$267
Ondansetron OdtOndansetron	19	$237
Levofloxacin	26	$178
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	11	$115
Ondansetron Hcl	13	$50

Paid to pharmacies, not to this prescriber.

Other internal medicine in Atlanta

Tracey HenryAtlanta$305K
Scott ParryAtlanta$162K
Jennifer GilliganAtlanta$162K
Tanna LimAtlanta$88K
Sally IwamotoAtlanta$60K
Antoine TrammellAtlanta$33K
Samuel AdamsAtlanta$30K
Jamal HajjariAtlanta$29K
Carlos SaldanaAtlanta$25K
Michael HicksonAtlanta$22K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →